Hybrid Advertising Auctions

Several major websites offer hybrid auctions that allow advertisers to bid on a per-impression or a per-click basis. We present the first analysis of this hybrid advertising auction setting. The conventional wisdom is that brand advertisers (e.g. Coca-Cola) will bid per impression, while direct response advertisers (e.g. Amazon.com) will bid per click. We analyze a theoretical model of advertiser bidding to ask whether this conventional wisdom will hold up in practice. We find the opposite in a static game: brand advertisers bid per click, while direct response advertisers bid per impression. In a more realistic repeated game, we find that direct response advertisers bid per click, but brand advertisers may profitably alternate between bidding for clicks and bidding for impressions. The analysis implies that sellers of online advertising (a) may sometimes prefer not to offer advertisers multiple bidding options, (b) should try to ascertain advertisers' types when they do use hybrid auctions, and (c) should consider advertisers' strategic incentives when forming click-through rate expectations in hybrid auction formats

Assessment of the Social and Physical Characteristics of Obiagu Shanty Area in Enugu Metropolitan City, Nigeria

The persistent rise of the urban population and high housing rent has driven many to shanty towns. However, due to the increased population of the shanty towns, the social and physical characteristics of the towns have deteriorated. The study assessed the social and physical characteristics of Obiagu Shanty Area in Enugu Metropolitan City, Nigeria, with the purpose of establishing the extent of the rehabilitation and its impacts in the lives of the residents, as well as provides a better alternative. The data was obtained using a questionnaire survey. The statistical techniques employed to analyse the data are descriptive statistics (such as simple percentages, standard deviation and mean). The study, in general terms identified that the level of physical and social characteristics of Obiagu Shanty Area is highly negative. The study also reveals poor infrastructural amenities in the area. It demonstrates that the government is failing to fulfill its responsibilities in terms of urban development and infrastructure renewal. Furthermore, the study shows that private individuals and communities do not actively participate in urban regeneration and infrastructural renewal efforts in Obiagu Shanty Area. Therefore, the study recommends some retrofitting measures, such as the construction of modern houses with modern facilities and good sewage systems, the government partnering with private organisations/individuals or the community to assist in the remodeling of structures in the area, and constant sensitisation of residents by the government and NGOs on the negative health consequences of living in a dirty environment, among other things. Keywords: Shanty Area, Social Characteristics, Physical Characteristics, Metropolitan City, Retrofitting Measures, Urban Regeneration DOI: 10.7176/JEES/12-9-05 Publication date:September 30th 202

Living and Studying in the US: An Ecological Systems Perspective

International students encounter many issues when living and studying in the United States. It is essential to understand how these adult students make meaning of these experiences. The purpose of this study was to gain insights into the meaning of the lived experiences of international students living and studying in the U.S. six months after returning to their home country. Phenomenology was the research approach used to explore participants’ perspectives of their lived experiences. Findings show how the interactions between participants’ development and the multiple systems they lived through influenced their experiences and perspectives and contributed to their identity development. Findings show the need for adult educators to be aware of the challenges and opportunities international students encounter and provide support to encourage growth and development

Newborn screening for cystic fibrosis

Since the late 1970s when the potential of the immunoreactive trypsinogen assay for early identification of infants with cystic fibrosis was first recognised, the performance of newborn blood spot screening (NBS) has been continually assessed and its use has gradually expanded. NBS for cystic fibrosis is a cost-effective strategy and, if standards of care are fully implemented and robust management pathways are in place, has a positive effect on clinical outcomes. In the past decade, NBS has undergone rapid expansion and an unprecedented number of infants with cystic fibrosis have access to early diagnosis and care. Cystic fibrosis NBS has now moved on from the development phase and is entering an era of consolidation. In the future, research should focus on the rationalisation and optimisation of existing programmes, with particular attention to bioethical implications such as unwanted detection of carriers and inconclusive diagnoses

Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.

Cystic fibrosis is a common life-shortening genetic disorder in the Caucasian population (less common in other ethnic groups) caused by the mutation of a single gene that codes for the production of the cystic fibrosis transmembrane conductance regulator protein. This protein coordinates the transport of salt (and bicarbonate) across cell surfaces and the mutation most notably affects the airways. In the lungs of people with cystic fibrosis, defective protein results in a dehydrated surface liquid and compromised mucociliary clearance. The resulting thick mucus makes the airway prone to chronic infection and inflammation, which consequently damages the structure of the airways, eventually leading to respiratory failure. Additionally, abnormalities in the cystic fibrosis transmembrane conductance regulator protein lead to other systemic complications including malnutrition, diabetes and subfertility.Five classes of mutation have been described, depending on the impact of the mutation on the processing of the cystic fibrosis transmembrane conductance regulator protein in the cell. In class I mutations, the presence of premature termination codons prevents the production of any functional protein resulting in a severe cystic fibrosis phenotype. Advances in the understanding of the molecular genetics of cystic fibrosis has led to the development of novel mutation-specific therapies. Therapies targeting class I mutations (premature termination codons) aim to mask the abnormal gene sequence and enable the normal cellular mechanism to read through the mutation, potentially restoring the production of the cystic fibrosis transmembrane conductance regulator protein. This could in turn make salt transport in the cells function more normally and may decrease the chronic infection and inflammation that characterises lung disease in people with cystic fibrosis.To evaluate the benefits and harms of ataluren and similar compounds on clinically important outcomes in people with cystic fibrosis with class I mutations (premature termination codons).We searched the Cochrane Cystic Fibrosis Trials Register which is compiled from electronic database searches and handsearching of journals and conference abstract books. We also searched the reference lists of relevant articles. Last search of Group's register: 24 October 2016.We searched clinical trial registries maintained by the European Medicines Agency, the US National Institutes of Health and the WHO. Last search of clinical trials registries: 28 November 2016.Randomised controlled trials of parallel design comparing ataluren and similar compounds (specific therapies for class I mutations) with placebo in people with cystic fibrosis who have at least one class I mutation. Cross-over trials were reviewed individually to evaluate whether data from the first treatment arm could be included. We excluded trials that combined therapies for premature termination codon class I mutations with other mutation-specific therapies.The authors independently assessed the risk of bias and extracted data from the included trial; they contacted trial authors for additional data.Our searches identified 28 references to eight trials; five trials were excluded (three were cross-over and one was not randomised and one did not have relevant outcomes), one cross-over trial is awaiting classification pending provision of data and one trial is ongoing. The included parallel randomised controlled trial compared ataluren to placebo for a duration of 48 weeks in 238 participants (age range 6 to 53 years) with cystic fibrosis who had at least one nonsense mutation (a type of class I mutation).The quality of evidence and risk of bias assessments for the trial were moderate overall. Random sequence generation, allocation concealment and blinding of trial personnel were well-documented; participant blinding was less clear. Some participant data were excluded from the analysis. The trial was assessed as high risk of bias for selective outcome reporting, especially when reporting on the trial's post hoc subgroup of participants by chronic inhaled antibiotic use.The trial was sponsored by PTC Therapeutics Incorporated with grant support by the Cystic Fibrosis Foundation, the Food and Drug Administration's Office of Orphan Products Development and the National Institutes of Health (NIH).The trial reported no significant difference between treatment groups in quality of life, assessed by the Cystic Fibrosis Questionnaire-Revised respiratory domain score and no improvement in respiratory function measures (mean difference of relative change in forced expiratory volume at one second 2.97% (95% confidence interval -0.58 to 6.52)). Ataluren was associated with a significantly higher rate of episodes of renal impairment, risk ratio 17.70 (99% confidence interval 1.28 to 244.40). The trial reported no significant treatment effect for ataluren for the review's secondary outcomes: pulmonary exacerbation; computerised tomography score; weight; body mass index; and sweat chloride. No deaths were reported in the trial.A post hoc subgroup analysis of participants not receiving chronic inhaled tobramycin (n = 146) demonstrated favourable results for ataluren (n = 72) for relative change in % predicted forced expiratory volume at one second and pulmonary exacerbation rate. Participants receiving chronic inhaled tobramycin appeared to have a reduced rate of pulmonary exacerbation compared to those not receiving chronic inhaled tobramycin. This drug interaction was not anticipated and may affect the interpretation of the trial results.There is currently insufficient evidence to determine the effect of ataluren as a therapy for people with cystic fibrosis with class I mutations. Future trials should carefully assess for adverse events, notably renal impairment and consider the possibility of drug interactions. Cross-over trials should be avoided given the potential for the treatment to change the natural history of cystic fibrosis

Kinesiology taping reduces the pain of finger osteoarthritis: a pilot single-blinded two-group parallel randomized trial

Objectives: Osteoarthritis (OA) is the most common arthropathy of the hand, and current treatments carry risks of adverse events. Supportive (kinesiology) tape may be analgesic and provide functional improvement, with a low risk of adverse outcomes. We experimented with supportive tape for OA of the proximal interphalangeal joint (PIPJ) of the finger in this pilot randomized trial. Methods: This two-group parallel randomized trial recruited adults with OA of the PIPJ of the finger. We excluded patients lacking capacity or the ability to safely apply the tape. Participants were randomized to receive kinesiology tape on the dorsum of the finger, blind to grouping. Pain was the primary outcome, which was recorded on a visual analog scale (VAS). Secondary outcomes were hand function and adverse reactions. Bootstrapped between-group analyses are reported. Results: Ten patients were included and randomized and provided complete data. There was no significant difference in pain between the groups (mean difference of 0.4 VAS units [95% confidence interval {CI} –1.6, 0.7], p=0.4). Overall, the application of kinesiology tape reduced reported pain by 6% (mean reduction of 0.6 VAS units [95% CI 0, 1.2], p=0.04). Taping did not affect hand function or digital range of motion. There were difficulties in recruiting individuals owing to the lack of dedicated research staff. Conclusion: Kinesiology taping may reduce the pain of OA in the finger; however, whether this is a true effect, placebo effect, Hawthorne phenomenon, or due to a statistical error (ie, type 1 error due to underpowering) is unclear. Hence, further trials are required

Cotton receipt, 6 January 1871

https://egrove.olemiss.edu/aldrichdocs/1262/thumbnail.jp

Cotton receipt, 2 December 1871

https://egrove.olemiss.edu/aldrichdocs/1267/thumbnail.jp

Cotton receipt, 30 December 1871

https://egrove.olemiss.edu/aldrichdocs/1265/thumbnail.jp